AspenBio files AppyScore with US FDA
This article was originally published in Clinica
AspenBio Pharma has filed a 510(k) application with the US FDA for its troubled appendicitis blood test, AppyScore. The product is an enzyme-linked immunosorbent assay (ELISA) test intended to be used in conjunction with other diagnostic methods, such as clinical exam or imaging, in patients with suspected appendicitis. AspenBio has persevered with the test, despite reporting disappointing results from a pivotal trial in January (see Clinica No 1333, p 27). The 510(k) submission includes data using a cut-off point of 14, which show a higher sensitivity and negative predictive value than with the original cut-off value of 20. The Castle Rock, Colorado firm is also developing a different version of AppyScore, a 15-minute rapid assay with reader instrument, which it hopes to start clinical trials with in early 2010.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.